28. Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman‐Boehm I, Kaddaha G, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011; 65(11): 1132-40.
29. Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial, including frequent patient–physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014; 10: 319-26.
30. Hassanein M, Hanif W, Malik W, Kamal A, Geransar P, Lister N, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011; 27(7): 1367-74.
31. Hassoun AA, Pathan MF, Medlej RC, Alarouj M, Shaltout I, Chawla MS, et al. Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study. Diabetes Metab Syndr Obes. 2016; 9: 225-31.
32. Khattab M, Mahmoud K, Shaltout I. Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study. Diabetes Ther. 2016; 7(3): 551-60.
33. Mahar SA, Hasan MI, Khan MI, Fawwad A, Hussain S, Maheshwary N, et al. Comparison of hypoglycaemia episodes in people with type-2 diabetes fasting in Ramazan, treated with vildaglipton or sulphonylurea: results of the Pakistani cohort of the VIRTUE study. J Pak Med Assoc. 2014; 64(11): 1297-302.
34. Al‐Arouj M, Hassoun AA, Medlej R, Pathan MF, Shaltout I, Chawla MS, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013; 67(10): 957-63.
35. Halimi S, Levy M, Huet D, Quéré S, Dejager S. Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: insights from the VERDI study. Diabetes Ther. 2013; 4(2): 385-98.
36. Aziz KM. Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes Metab Syndr Obes. 2015; 8: 207-11.
37. Schweizer A, Halimi S, Dejager S. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan. Vasc Health Risk Manag. 2014; 10: 15-24.
38. Hanif W, Malik W, Hassanein M, Kamal A, Geransar P, Andrews C, et al. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. Curr Med Res Opin. 2013; 29(7): 807-11.
39. Shete A, Shaikh A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, et al. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes. 2013; 4(6): 358-64.
40. Mudher Mikhael E. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. J Diabetes Res. 2016; 2016: 1-11.
41. Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berrah A, Omar M, et al. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial. Diabetes Obes Metab. 2016; 18(10): 1025-33.
42. Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, et al. A randomized controlled trial comparing the GLP‐1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial. Diabetes Obes Metab. 2014; 16(6): 527-36.
43. Bashier A, Khalifa AA, Abdelgadir EI, Al Saeed MA, Al Qaysi AA, Bayati MBA, et al. Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes. Oman Med J. 2018; 33(2): 104-10.
44. Hassanein M, Echtay A, Hassoun A, Alarouj M, Afandi B, Poladian R, et al. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). Int J Clin Pract. 2017; 71(10).
45. Kelwade J, Sethi BK, Vaseem A, Nagesh VS. Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow. Indian J Endocrinol Metab. 2014; 18(6): 874-5.
46. Maideen NMP, Balasubramaniam R. Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs. J Herbmed Pharmacol. 2018; 7(3): 200-10.
47. Maideen NMP. Pharmacokinetic and Pharmacodynamic Interactions of Sulfonylurea Antidiabetics. Eur J Med. 2018; 6(2): 83-96.
48. Aravind SR, Al Tayeb K, Ismail SB, Shehadeh N, Kaddaha G, Liu R, et al. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011; 27(6): 1237-42.
49. Ahmed MH, Husain NE, Elmadhoun WM, Noor SK, Khalil AA, Almobarak AO. Diabetes and Ramadan: A concise and practical update. J Family Med Prim Care. 2017; 6(1): 11-8.
50. Pakkir Maideen NM, Manavalan G, Balasubramanian K. Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter. Ther Adv Endocrinol Metab. 2018: 9(8): 259-68.
51. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: practical guidelines. Diabetes Res Clin Pract. 2017; 126: 303-16.
52. Pakkir Maideen NM. Thiazolidinediones and their Drug Interactions involving CYP enzymes. American Journal of Physiology, Biochemistry and Pharmacology. 2018; 8(2): 47-54.
53. Almalki MH, Alshahrani F. Options for controlling type 2 diabetes during Ramadan. Front Endocrinol (Lausanne). 2016; 7: 32.
54. Ahmed MH, Husain NE, Elmadhoun WM, Noor SK, Khalil AA, Almobarak AO. Diabetes and Ramadan: A concise and practical update. J Family Med Prim Care. 2017; 6(1): 11-8.
55. Vasan S, Thomas N, Bharani AM, Abraham S, Job V, John B, et al. A double-blind, randomized, multicenter study evaluating the effects of pioglitazone in fasting Muslim subjects during Ramadan. Int J Diabetes Dev Ctries. 2006; 26(June): 70-6.
56. Kalra S. Alpha glucosidase inhibitors. J Pak Med Assoc. 2014; 64(4): 474-6.
57. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. Diabet Med. 2008; 25(4): 435-41.
58. Pathan MF, Sahay RK, Zargar AH, Raza SA, Khan AK, Ganie MA, et al. South Asian Consensus Guideline: use of insulin in diabetes during Ramadan. Indian J Endocrinol Metab. 2012; 16(4): 499-502.
59. Benbarka MM, Khalil AB, Beshyah SA, Marjei S, Awad SA. Insulin pump therapy in Moslem patients with type 1 diabetes during Ramadan fasting: an observational report. Diabetes Technol Ther. 2010; 12(4): 287-90.
60. Akbani MF, Saleem M, Gadit WU, Ahmed M, Basit A, Malik RA. Fasting and feasting safely during Ramadan in the patient with diabetes. Pract Diabetes Int. 2005; 22(3): 100-4.
61. Niazi AK, Kalra S. Patient centred care in diabetology: an Islamic perspective from South Asia. J Diabetes Metab Disord. 2012; 11(1): 30.
62. Beshyah SA, Benbarka MM, Sherif IH. Practical management of diabetes during Ramadan fast. Libyan J Med. 2007; 2(4): 185-9.
63. Hossain K, Zehra T. Diabetes and diet in Ramadan. JPMA. J Pak Med Assoc. 2015; 65(5 Suppl 1): S72-5.
64. Karamat MA, Syed A, Hanif W. Review of diabetes management and guidelines during Ramadan. J R Soc Med. 2010; 103(4): 139-47.
65. Qureshi B. Diabetes in Ramadan. J R Soc Med. 2002; 95(10): 489-90.
66. Masood SN, Sheikh MA, Masood Y, Hakeem R, Shera AS. Beliefs of people with diabetes about skin prick during Ramadan fasting. Diabetes Care. 2014; 37(4): e68-9.
67. Eid YM, Sahmoud SI, Abdelsalam MM, Eichorst B. Empowerment-based diabetes self-management education to maintain glycemic targets during Ramadan fasting in people with diabetes who are on conventional insulin: a feasibility study. Diabetes Spectr. 2017; 30(1): 36-42.
68. Zainudin SB, Abu Bakar KNB, Abdullah SB, Hussain AB. Diabetes education and medication adjustment in Ramadan (DEAR) program prepares for self-management during fasting with tele-health support from pre-Ramadan to post-Ramadan. Ther Adv Endocrinol Metab. 2018: 9(8): 231-40.
69. Ahmedani MY, Hashmi BZ, Ulhaque MS. Ramadan and diabetes-knowledge, attitude and practices of general practitioners; a cross-sectional study. Pak J Med Sci. 2016; 32(4): 84650.
70. Al Slail FY, Rashid HU, Fadl SM, Kheir OO. Physician Awareness in Diabetes Management During Ramadan 2015—A Focus Group Discussion. US Endocrinol. 2017; 13(1): 30-4.
71. Ibrahim OH. Pharmacist Role in Pharmaceutical Care during Ramadan. Pharmacol Pharm. 2015; 6(12): 589.
72. Bukhari N. How pharmacists can support and advise patients during Ramadan. Pharm J. 2016; 15: 05.
73. Wilbur K, Al Tawengi K, Remoden E. Diabetes patient management by pharmacists during Ramadan. BMC Health Serv Res. 2014; 14(1): 117.
74. Adnan M, Khaliq A, Fahad M, Hussaini SA, Karim S. Pharmacists’ Management of Diabetes during Ramadan Fasting. Ibnosina Journal of Medicine and Biomedical Sciences. 2016; 8(5): 160-7.
75. Amin ME, Chewning B. Community pharmacists’ knowledge of diabetes management during Ramadan in Egypt. Int J Clin Pharm. 2014; 36(6): 1213-21.
76. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: practical guidelines. Diabetes Res Clin Pract. 2017; 126: 303-16.
77. Bajaj HS, Abouhassan T, Ahsan MR, Arnaout A, Hassanein M, Houlden RL, et al. Diabetes Canada Position Statement for People With Types 1 and 2 Diabetes Who Fast During Ramadan. Can J Diabetes. 2019; 43(1): 3-12.